Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate HighlightsGlobeNewsWire • 05/02/24
Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024GlobeNewsWire • 04/25/24
Does Relay Therapeutics, Inc. (RLAY) Have the Potential to Rally 146.52% as Wall Street Analysts Expect?Zacks Investment Research • 03/13/24
Wall Street Analysts See a 131.6% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High?Zacks Investment Research • 02/26/24
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate HighlightsGlobeNewsWire • 02/22/24
Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024GlobeNewsWire • 02/15/24
Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 02/15/24
Relay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last?Zacks Investment Research • 02/15/24
Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceGlobeNewsWire • 02/01/24
Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/02/24
Wall Street Analysts Think Relay Therapeutics, Inc. (RLAY) Could Surge 189.21%: Read This Before Placing a BetZacks Investment Research • 11/30/23
Wall Street Analysts See a 202.33% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High?Zacks Investment Research • 11/14/23
Relay Therapeutics: Market Is Underestimating Lirafugratinib's Potential (Rating Upgrade)Seeking Alpha • 11/06/23
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate HighlightsGlobeNewsWire • 11/02/23
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid TumorsGlobeNewsWire • 10/12/23
Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 09/18/23
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/08/23
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate HighlightsGlobeNewsWire • 08/08/23
Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023GlobeNewsWire • 08/01/23